The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://murrayrkaa304938.jiliblog.com/95147929/retatrutide-vs-tirzepatide-a-comparative-analysis